NASDAQ:EIGR - Eiger BioPharmaceuticals, Inc.
$11.03
 $-2.00
-15.35%
4:00PM EDT
2019-04-18
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  EIGR     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 38   203. 85   241. 91  
42 stocks rank:  3. 98 K 1. 44 K 1. 05 K
# analyst opinions:  6. 00   14. 51   13. 97  
mean recommendation:  1. 20   2. 09   2. 01  

quick ratio:  10. 01   5. 27   1. 81  
current ratio:  10. 16   5. 62   2. 25  

target price low:  21. 00   84. 80   115. 21  
target price avg:  11. 51   111. 51   137. 51  
target price high:  14. 96   135. 81   157. 84  
1-yr high:  16. 80   114. 23   138. 78  
last close:  11. 03   87. 66   116. 69  
50-day avg:  13. 73   95. 54   123. 44  
200-day avg:  12. 00   94. 25   121. 11  
1-yr low:  8. 30   72. 78   98. 34  
volume:  1. 27 M 4. 11 M 8. 07 M
50-day avg volume:  97. 63 K 2. 76 M 5. 02 M
200-day avg volume:  114. 03 K 2. 92 M 4. 59 M

1-day return:  -15. 35 % -0. 41 % 0. 07 %
this week return:  -22. 43 % -5. 74 % -4. 11 %
12-wk return:  -22. 87 % 1. 61 % -0. 05 %
52-wk return:  30. 95 % 3. 12 % 8. 78 %

enterprise value (EV):  137. 71 M 48. 94 B 114. 64 B
market cap:  212. 44 M 43. 07 B 104. 73 B
EBITDA:  -50. 99 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -2. 70   4. 22   12. 73  
total debt:  25. 62 M 12. 24 B 16. 73 B
debt/equity:  38. 47   46. 71   89. 62  
net income (common):  -52. 39 M 2. 20 B 4. 20 B

shares outstanding:  19. 26 M 571. 70 M 1. 24 B
shares:  9. 73 M 571. 81 M 1. 23 B
shares short:  128. 28 K 10. 17 M 13. 00 M
shares short prior month:  125. 14 K 9. 54 M 17. 33 M
short ratio:  1. 78   5. 41   3. 28  
short % of float:  1. 88 % 5. 45 % 2. 38 %
total cash/share:  5. 21   11. 14   9. 33  
total cash:  100. 35 M 6. 71 B 7. 15 B
free cash flow:  -24. 46 M 3. 58 B 2. 96 B
operating cash flow:  -42. 67 M 4. 15 B 4. 30 B

book value:  3. 47   12. 78   26. 92  
price/book:  3. 18   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  41. 77 % --- ---
1-yr mean volatility:  0. 12 % 0. 03 % 0. 04 %

1-yr EPS:  -3. 82   2. 40   4. 10  
forward EPS:  -2. 52   3. 97   7. 13  
P/E:  -2. 89   13. 63   22. 72  
forward P/E:  -4. 38   -15. 95   13. 99  
PE/G:  0. 19   -1. 65   -1. 32  
growth:  -14. 90 % 127. 12 % 29. 61 %
earnings high:  -0. 74   1. 00   1. 66  
earnings avg:  -0. 97   0. 77   1. 53  
earnings low:  -1. 33   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -43. 91 % -2. 75 % 4. 55 %
return on equity:  -117. 58 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  1. 49   1. 25   0. 93  
sharpe (1yr):  0. 42   0. 37   0. 70  

held % insiders:  1. 88 % 6. 39 % 3. 38 %
held % institutions:  81. 31 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : EIGR
.        + 0 =             0 :: INITIAL WEIGHT
.   + 52.514 =        52.514 :: inverse volume-to-price addition
.    + 45.51 =        98.024 :: spline projection addition
.    x 2.151 =       210.829 :: 13 weeks' performance factor
.    x 1.071 =       225.771 :: one-year gains+dividend factor
.    x 1.431 =       323.175 :: industry recommendation factor
.    x 3.264 =      1054.711 :: symbol recommendation factor
.    x 0.996 =       1050.08 :: return on assets factor
.    x 0.988 =      1037.733 :: return on equity factor
.    x 2.194 =      2276.302 :: current ratio factor
.    x 1.054 =      2399.287 :: quick ratio factor
.     x 1.25 =      2998.435 :: short ratio factor
.    x 2.032 =       6092.29 :: price-to-book factor
.     x 1.35 =      8227.014 :: debt-to-equity factor
.    x 1.099 =      9038.285 :: 5-day avg > 200-day avg
.    x 1.144 =     10342.773 :: 50-day avg > 200-day avg
.    x 2.127 =     21998.666 :: P/E weight
.    x 1.507 =      33158.49 :: PE/G factor
.    x 1.466 =     48624.875 :: beta factor
.    x 0.418 =     20348.942 :: sharpe factor
.    x 2.057 =     41859.559 :: target low factor
.     x 1.07 =     44780.212 :: target mean factor
.     x 1.06 =     47453.378 :: target high factor
.     x 1.31 =     62158.605 :: industry 2-weeks return factor
.    x 0.945 =     58738.035 :: "drift" penalty 2 days ago
.    x 0.918 =     53924.211 :: "drift" penalty 4 days ago
.    x 0.822 =     44310.466 :: "drift" penalty 5 days ago
.    x 0.994 =     44033.603 :: overall "drift" factor
.    x 0.582 =     25639.824 :: largest single-day jump factor
.    x 0.163 =      4169.077 :: low price factor
.      x 1.0 =        4168.4 :: factor hist industry gain for week 16
.   cubeRoot =        16.094 :: reduced to standardize
.   - 19.291 =         0.375 :: add/subtract for performance
.                      0.375 :: FINAL WEIGHT for NASDAQ:EIGR


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org